LEXXW
Income statement / Annual
Last year (2024), Lexaria Bioscience Corp.'s total revenue was $464,278.00,
an increase of 105.24% from the previous year.
In 2024, Lexaria Bioscience Corp.'s net income was -$5.80 M.
See Lexaria Bioscience Corp.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
08/31/2024 |
08/31/2023 |
08/31/2022 |
08/31/2021 |
08/31/2020 |
08/31/2019 |
08/31/2018 |
08/31/2017 |
08/31/2016 |
08/31/2015 |
Operating Revenue |
$464,278.00 |
$226,208.00 |
$255,397.00 |
$722,738.00 |
$384,543.00 |
$222,610.00 |
$433,287.00 |
$63,639.00 |
$40,718.00 |
$14,702.00 |
Cost of Revenue |
$4,822.00
|
$31,500.00
|
$71,841.00
|
$175,346.00
|
$99,378.00
|
$22,893.00
|
$25,185.00
|
$29,750.00
|
$45,615.00
|
$29,883.00
|
Gross Profit |
$459,456.00
|
$194,708.00
|
$183,556.00
|
$547,392.00
|
$285,165.00
|
$199,717.00
|
$408,102.00
|
$33,889.00
|
-$4,897.00
|
-$15,181.00
|
Gross Profit Ratio |
0.99
|
0.86
|
0.72
|
0.76
|
0.74
|
0.9
|
0.94
|
0.53
|
-0.12
|
-1.03
|
Research and Development Expenses |
$2.36 M
|
$3.67 M
|
$1.84 M
|
$1.26 M
|
$387,074.00
|
$555,730.00
|
$492,864.00
|
$54,185.00
|
$9,024.00
|
$146,466.00
|
General & Administrative Expenses |
$3.85 M
|
$3.06 M
|
$5.72 M
|
$4.97 M
|
$3.57 M
|
$3.13 M
|
$6.02 M
|
$1.63 M
|
$1.01 M
|
$1.49 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$204,277.00
|
$515,360.00
|
$489,058.00
|
$209,034.00
|
$185,459.00
|
$276,560.00
|
Selling, General & Administrative Expenses |
$3.85 M
|
$3.06 M
|
$5.72 M
|
$4.97 M
|
$3.77 M
|
$3.64 M
|
$6.51 M
|
$1.84 M
|
$1.20 M
|
$1.76 M
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$112,750.00
|
$60,550.00
|
$2,307.00
|
-$886.00
|
$4,602.00
|
-$22,664.00
|
Operating Expenses |
$6.21 M
|
$6.73 M
|
$7.57 M
|
$6.23 M
|
$4.27 M
|
$4.26 M
|
$7.01 M
|
$1.90 M
|
$1.21 M
|
$1.91 M
|
Cost And Expenses |
$6.22 M
|
$6.76 M
|
$7.64 M
|
$6.41 M
|
$4.37 M
|
$4.28 M
|
$7.03 M
|
$1.92 M
|
$1.26 M
|
$1.94 M
|
Interest Income |
$14,311.00
|
$43,190.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$6,015.00
|
$2,250.00
|
$31,544.00
|
Depreciation & Amortization |
$76,153.00
|
$145,397.00
|
$146,914.00
|
$147,597.00
|
$146,092.00
|
$60,550.00
|
$2,307.00
|
$1,488.00
|
$619.00
|
-$22,664.00
|
EBITDA |
-$5.68 M |
-$6.39 M |
-$6.52 M |
-$5.58 M |
-$4.00 M |
-$4.10 M |
-$6.61 M |
-$1.92 M |
-$1.26 M |
-$1.95 M |
EBITDA Ratio |
-12.23
|
-28.24
|
-28.36
|
-9.77
|
-9.83
|
-17.52
|
-15.23
|
-29.22
|
-29.84
|
-132.69
|
Operating Income Ratio |
-12.39
|
-28.89
|
-28.91
|
-7.87
|
-10.12
|
-17.79
|
-15.23
|
-29.25
|
-29.85
|
-131.15
|
Total Other Income/Expenses Net |
-$55,524.00
|
-$178,503.00
|
-$764,614.00
|
$1.52 M
|
$0.00
|
-$228,060.00
|
-$8,968.00
|
-$6,015.00
|
-$34,698.00
|
-$55,058.00
|
Income Before Tax |
-$5.81 M
|
-$6.71 M
|
-$7.38 M
|
-$4.16 M
|
-$4.08 M
|
-$4.16 M
|
-$6.61 M
|
-$1.93 M
|
-$1.28 M
|
-$1.98 M
|
Income Before Tax Ratio |
-12.51
|
-29.67
|
-28.91
|
-5.76
|
-10.62
|
-18.68
|
-15.25
|
-30.32
|
-31.37
|
-134.9
|
Income Tax Expense |
$0.00
|
$0.00
|
-$114,329.00
|
-$1.66 M
|
-$54,286.00
|
$39,623.00
|
-$8,968.00
|
-$54,173.00
|
-$60,226.00
|
-$181,226.00
|
Net Income |
-$5.80 M
|
-$6.66 M
|
-$7.27 M
|
-$2.50 M
|
-$4.03 M
|
-$4.20 M
|
-$6.60 M
|
-$1.87 M
|
-$1.21 M
|
-$1.77 M
|
Net Income Ratio |
-12.48
|
-29.46
|
-28.46
|
-3.47
|
-10.48
|
-18.86
|
-15.23
|
-29.37
|
-29.83
|
-120.43
|
EPS |
-0.47 |
-1.01 |
-1.24 |
-0.57 |
-1.45 |
-1.62 |
-2.79 |
-0.95 |
-0.83 |
-1.34 |
EPS Diluted |
-0.47 |
-1.01 |
-1.24 |
-0.57 |
-1.45 |
-1.62 |
-2.79 |
-0.95 |
-0.83 |
-1.34 |
Weighted Average Shares Out |
$12.38 M
|
$6.61 M
|
$5.89 M
|
$4.39 M
|
$2.77 M
|
$2.59 M
|
$2.37 M
|
$1.96 M
|
$1.46 M
|
$1.32 M
|
Weighted Average Shares Out Diluted |
$12.38 M
|
$6.61 M
|
$5.89 M
|
$4.39 M
|
$2.77 M
|
$2.59 M
|
$2.37 M
|
$1.96 M
|
$1.46 M
|
$1.32 M
|
Link |
|
|
|
|
|
|
|
|
|
|